Clinical Trials Browser

Phase 3 × Has results × venetoclax × Clear all

NCT03462719 2026-04-13

GLOW

Phase 3 Active not recruiting

211 enrolled 23 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03737981 2026-04-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Phase 3 Active not recruiting

465 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04102020 2026-04-08

VIALE-M

Phase 3 Completed

112 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04285567 2026-03-03

CRISTALLO

Phase 3 Completed

166 enrolled 27 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase 3 Completed

445 enrolled 22 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Phase 3 Completed

211 enrolled 30 charts 3 FDA

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

Phase 3 Active not recruiting

443 enrolled 14 charts 3 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03112174 2025-07-22

SYMPATICO

Phase 3 Completed

366 enrolled 45 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05079230 2025-04-04

ENHANCE-3

Phase 3 Terminated

378 enrolled 29 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04778397 2025-02-05

ENHANCE-2

Phase 3 Terminated

258 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02005471 2023-10-17

MURANO

Phase 3 Completed

389 enrolled 35 charts 4 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02755597 2023-08-22

Bellini

Phase 3 Completed

291 enrolled 24 charts

Multiple Myeloma

NCT02756611 2023-04-10

VENICE I

Phase 3 Completed

258 enrolled 27 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Phase 3 Completed

60 enrolled 12 charts

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT02980731 2023-02-22

VENICE II

Phase 3 Completed

210 enrolled 36 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell